The study presents the FAST platform, which rapidly designs and tests antisense therapies targeting essential and non-essential genes in multidrug-resistant (MDR) bacteria. Key findings include the identification of several gene targets, such as gyrB, rpsD, and others, which showed significant growth inhibition when targeted by PNA therapies.